Levocetirizine hydrochloride granules, a class 5 new drug of Kangzhi pharmaceutical, has obtained the production approval

In the afternoon of June 16, Kangzhi pharmaceutical released a notice that the company recently received the registration approval document of levocetirizine hydrochloride granules approved and issued by the State Food and drug administration, which is valid until May 26, 2020 Levocetirizine hydrochloride granules are suitable for children and adults aged 2 years and over The suitable diseases are urticaria, allergic rhinitis, eczema, dermatitis, pruritus, etc At present, the tablets and capsules of the drug have been sold in the domestic market The company said that the approval of the drug further enriched the product category of the company's children's drug and optimized the company's product structure At present, the company has started to arrange production according to the market demand Appendix: announcement of Hainan Kangzhi Pharmaceutical Co., Ltd on obtaining the registration approval document of levocetirizine hydrochloride granules, the company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, without false records, misleading statements or major omissions Hainan Kangzhi Pharmaceutical Co., Ltd (hereinafter referred to as "the company") recently received the registration approval of levocetirizine hydrochloride granules approved and issued by the State Food and drug administration The specific information of the registration approval is as follows: 1 Drug name: levocetirizine hydrochloride granules; 2 Specification: 2.5mg; 3 Approval No.: 2015s00414; 4 Registration classification: chemical medicine category 5; 5 Approval document No.: gyzz h20150042; 6 Validity of drug approval document No.: until May 26, 2020 Levocetirizine hydrochloride granules are suitable for children and adults aged 2 years and over The suitable diseases are urticaria, allergic rhinitis, eczema, dermatitis, pruritus, etc At present, the tablets and capsules of the drug have been sold in the domestic market The approval documents of the drug further enrich the product categories of the company's children's drugs and optimize the product structure of the company At present, the company has started to arrange production according to the market demand, but the specific sales situation of the product in the future may be affected by market environment changes and other factors, with uncertainty Please make careful decisions and pay attention to prevent investment risks It is hereby announced Board of directors of Hainan Kangzhi Pharmaceutical Co., Ltd June 16, 2015